To test our hypothesis that PIM kinase inhibition might de-stabilize MYC protein and thus recapitulate the effect of MYC shRNA, we treated two MPN cell lines, SET2 and UKE1, with three pan-PIM inhibitors representing distinct chemical classes (Supplementary Fig. 5). Here, MYC is linked to myeloproliferative neoplasm.